Lexatumumab

Tax included
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research.
MedChemExpress 
HY-P99299

Data sheet

Size
Multiple sizes
Reactivity
Apoptosis
Application
Cancer-programmed cell death
CAS
845816-02-6